Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/1346-8138.14641 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pustular and crusted lesions in systemic lupus erythematosus: A case report.
J Family Med Prim Care
November 2024
Department of Dermatology, Venereology and Leprosy, SRM Medical College and Research Centre, Chengalpattu, Tamil Nadu, India.
Systemic lupus erythematosus (SLE) is the prototype of an autoimmune disease with various manifestations in the skin and several other organs. Subacute cutaneous lupus erythematosus may present with annular and psoriasiform lesions. There have been case reports of pustular lesions in SLE.
View Article and Find Full Text PDFUnveiling the Role of Resident Memory T Cells in Psoriasis.
J Leukoc Biol
December 2024
Departamento de Biología, Facultad de Ciencias, Universidad de Chile.
Psoriasis is a chronic inflammatory skin disease characterized by periods of remission and relapse. In this pathology, keratinocytes, dendritic cells, and different subpopulations of T cells are critical to developing psoriatic lesions. Although current treatments can reduce symptoms, they reappear in previously injured areas months after stopping treatment.
View Article and Find Full Text PDFDose reduction and discontinuation of biologic and targeted synthetic disease-modifying anti-rheumatic drugs (DMARDs) for people with psoriatic arthritis in remission or low disease activity.
Cochrane Database Syst Rev
December 2024
School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia.
This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To determine the benefits and harms of dose reduction or discontinuation of biologic disease-modifying anti-rheumatic drugs or targeted synthetic disease-modifying anti-rheumatic drugs in adults with psoriatic arthritis who are in remission or a low disease activity state.
View Article and Find Full Text PDFDevelopment and external validation of a prediction model for the risk of relapse in psoriasis after discontinuation of biologics.
Front Med (Lausanne)
November 2024
Department of Dermatology, China-Japan Friendship Hospital, National Center for Integrative Chinese and Western Medicine, Beijing, China.
Background: Some patients with psoriasis experience relapses shortly after discontinuation of biologics. However, there is a lack of risk prediction tools to identify those at high risk of relapse.
Objective: To develop and validate a risk prediction model for psoriasis relapse after biologics discontinuation.
Proactive therapeutic drug monitoring of biologic drugs in patients with inflammatory bowel disease, inflammatory arthritis, and psoriasis: systematic review and meta-analysis.
BMJ Med
October 2024
MAGIC Evidence Ecosystem Foundation, Oslo, Norway.
Objective: To address the efficacy and safety of proactive therapeutic drug monitoring of biologic drugs for patients with inflammatory bowel disease, inflammatory arthritis, and psoriasis.
Design: Systematic review and meta-analysis.
Data Sources: Medline, Embase, Central, and CINAHL, from database inception to 23 May 2024.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!